The purpose of this study was to assess the effects of the calcium entry blocker nicardipine and alpha human atrial natriuretic peptide (hANP) on antihypertensive and diuretic activity in hypertensive surgical patients. The site of the diuretic actions of these drugs along the nephron were also investigated by measuring the excretion rate of inorganic phosphate (P04
diuresis, but the site of action of the two drugs on the nephron may be different. Phosphate reabsorption is considered to occur largely in the renal proximal tubule, so that its appearance in the urine in increased quantities without the change of renal circulation in the nicardipine group suggests a proximal tubular action of this drug. However, the site of action of hANP in the kidney was not determined because GFR increased and distal sodium reabsorption was suppressed due to the drug infusion.

Cette #tude ~value les effets de l'inhibiteur calcique nicardipine et du peptide atrial alpha natriurique humain (hANP) sur l'activit~ antihypertensive et diur~tique chez le patient hypertendu. Sur le n~phron, on a aussi recherchd le site de l' activitd diur~tique de ces produits par la mesure de la vitesse d' excrdtion du phosphate inorganique (P04)
the fractional excretion of sodium (FENa). These two analyses of the reabsorption of electrolytes can then be used to postulate the site of action of a drug on the renal tubule in clinical study.
Many calcium (Ca) entry blocking drugs are currently undergoing clinical investigation for hypertensive surgical patients. These drugs may be more effective than high concentration of inhalation anaesthetics for maintaining the renal circulation and diuresis during the control of blood pressure, because an increase in glomerular filtration rate (GFR) and sodium diuresis often accompanies their administration to hypertensive subjects.l However, only a few of these drugs have been studied sufficiently well to permit clinical characterization of their renal effects. 2 Differences have also been observed in the response of normotensive and hypertensive patients to Ca antagonists in clinical studies. 3~ A change of renal perfusion has been suggested as one of the important mechanisms involved in sodium diuresis due to Ca antagonists. However, in animal studies s'6 in which blood pressure was decreased, Ca antagonists accelerated the natriuretic effect without altering renal blood flow (RBF) or GFR. These findings suggest that the mechanism of the diuresis is not solely alteration of the renal circulation, but also inhibition of sodium reabsorption in the renal tubules. These unresolved problems have encouraged further research to examine the effect of the popular Ca antagonist, nicardipine, on renal perfusion and renal tubular electrolyte reabsorption in hypertensive surgical patients under general anaesthesia.
We also investigated the renal effects of alpha human atrial natriuretic peptide (hANP), because the effect of hANP on RBF has been found to be variable in animal studies, although an increase in GFR has usually been observed following ANP infusion. 7-8 These renal haemodynamic effects of ANP are unique when compared with the actions of previously studied vasodilatory agents. However, Richards et al. 9 reported that the effects of intravenous hANP on blood pressure in conscious humans are variable because reflex sympathetic stimulation may counter the decrease in blood pressure caused by hANPinduced vasodilatation. 9-1~
The antihypertensive effects of nicardipine and hANP were compared, and the sites of the diuretic actions of these drugs along the nephron were also investigated by measuring the excretion of inorganic phosphate (PO4) in this study. Since PO 4 reabsorption is considered to occur mainly in the early proximal renal tubule, its appearance in the urine in increased quantities suggests a proximal tubular effect of diuretic agents, l~ The distal tubular reabsorption of sodium can be determined from the difference in the fractional excretion of PO 4 (FEPO4) and
Methods
Thirty-two patients (20 men and 12 women aged 30-69 yr) undergoing gastrectomy for gastric cancer or gastric ulcer were included in the study. The studies were carded out according to the principles of the Declaration of Helsinki. No drugs were administered to the patients simply for the purpose of data acquisition. Informed written consent to the protocol, which was approved by the University Hospital Review Board, was obtained from each of the subjects. The criterion of hypertension in this study was a systolic BP over 160 mmHg during surgery. The patients had no history of renal disease and the plasma creatinine concentration before surgery was less than 1.5 mg-d1-1 in all patients.
All operations were begun between 9:00 and 10:00 am. The patients did not receive antihypertensive agents on the morning of surgery. Before the induction of anaesthesia, a 16-gauge teflon catheter was inserted into an antecubital vein for fluid and drug administration. Anaesthesia was induced with intravenous thiopentone (5 mg. kg -I) and vecuronium bromide (0.15 mg. kg -t) was given to facilitate tracheal intubation. Ventilation was controlled with a mechanical ventilator and the arterial carbon dioxide pressure (PaCO2) was maintained at 35--44 mmHg. Anaesthesia was maintained with N20 (4 L. min-l), O z (2 L. min -1) and enflurane (1.0-2.0% of inspired concentration). Immediately after the induction of anaesthesia, a 22-gauge teflon catheter was inserted percutaneously into the radial artery to measure the blood pressure, as well as for arterial blood gas analysis and the collection of blood samples. Urine samples were collected every 20 rain via an indwelling bladder catheter inserted after the induction of anaesthesia. Suprapubic pressure and bladder washout with air were used to ensure emptying of the bladder. Ringer's lactate solution was administered at a rate of 10 ml. kg -l 9 hr -l iv to all patients during the study. No blood transfusions were given because the blood loss was <200 ml during the study in all cases. The blood pressure was treated after collecting a urine sample for 20 min.
The 32 patients were randomly allocated to three groups. In Group 1 (n --11) hypertension was treated by increasing the inspired concentration of enflurane. In Group 2 (n = 11), BP was maintained within 110-150 mmHg by controlling the rate of infusion of nicardipine (0.5-2.0 ~.g. kg -l. min-l). In Group 3 (n = 10), BP was maintained at 110-150 mmHg by varying the rate of hANP infusion (0.05-0.2 p,g. kg -I. min-l). The concen-trafions of N20 and enflurane were not changed during the infusion of nicardipine and hANP in Groups 2 and 3 during hypertension and following the treatment.
An initial 20 min urine sample was obtained during hypertension but before treatment. Two further 20 min samples were obtained after BP was controlled to 110-150 mmHg.
The sodium concentrations of plasma and urine were determined by flame photometry. Plasma osmolarity was measured using a Knauer osmometer. Urine and plasma concentrations of PO n and creatinine were determined colorimetrically.
Osmotic clearance (Cosm), FENa, FEPOn, the fractional distal reabsorption of sodium (FDRNa), and the distal tubular rejection fraction of sodium (DTRFNa) were calculated from the following formulae:
where Vu is the urine output (ml. min-l), Uosm and Posm respectively are the urinary and plasma osmolarity (mOsm-L-t), UNa and UPO n are the urinary concentrations of sodium (mEq. L-I), and PO,, (mg. dl-l), PNa and PPO 4 are the plasma concentrations of sodium (mEq. L -l) and PO 4 (mg" dl-l), and Ccr is the creatinine clearance (ml. min-1). The FDRNa has been calculated from the fractional excretion of lithium and FENa in other reports, 12-13 but, as we could not infuse lithium into our surgical patients, FEPO 4 was used for the calculation of FDRNa instead of lithium clearance.
The parametric data were analyzed by one-way analysis of variance, and non-parametric data were analysed by the Friedman test and the Kruskal-Wallis test for multiple comparisons. Correlations between the increases of FENa (AFENa) and FEPO,, (AFEPO4) were calculated from the difference between, before and during nicardipine infusion and the correlation coefficient was calculated by Pearson' s test in Group 2. Simple linear regression analysis was done by the least squares method.
Results are presented as the mean _+ SD, and a value of P < 0.05 was taken to indicate a significant difference.
Drugs
The following drugs were used: 1 Nicardipine hydrochloride (2,6-dimethyl-4(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid-3-(2-(N-benzyl-N-methylamino))-ethyl ester 5-methyl ester hydrochloride) was obtained from Yamanouchi Pharmaceutical Company, Japan. 2 Alpha human atrial natriuretic peptide (Ser-Leu-Arg- Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-IleGly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-ArgTry) was obtained from Suntory Pharmaceutical Company, Japan.
Results
There were no differences in the sex, age, and body weight among the three groups (Table I ). The mean inspired concentrations ofenflurane during the hypertensive period were 1.8 ___ 0.2%, 1.9 • 0.1%, and 1.8 _ 0.2% in Groups 1, 2 and 3, respectively. In Group 1, the enflurane concentration was increased to 2.9 ---0.3% during the period of blood pressure control. Systolic and diastolic blood pressure were decreased (P < 0.01) 20 min after the start of infusion of nicardipine or hANP in Groups 2 and 3 (Table II) . The Ccr increased (P < 0.05) in Group 3, but did not change in Groups 1 and 2 (Table III) . Urine volume, sodium and PO 4 excretion were increased in Groups 2 and 3 (P < 0.01). The increase of urine volume in Group 3 was greater than in Group 2 (P < 0.05). The FENa and FEPO 4 alSO increased in Groups 2 and 3, but did not change in Group 1 (Table IV) . The FDRNa decreased and DTRFNa increased (P < 0.05) during hANP infusion in Group 3, but did not change in (Table II) .
Discussion
The main findings of our study were that enflurane, nicardipine and hANP all decreased arterial pressure to the same extent. During infusion of nicardipine a diuresis and phosphaturia were observed in all patients regardless of the GFR and plasma PO 4 levels, whilst the fractional distal reabsorption of sodium did not change. These data suggest that nicardipine induced phosphaturic diuresis by inhibition of electrolyte reabsorption in the proximal renal tubule. In clinical studies analyzing the mechanism of the diuretic action of Ca antagonists, sodium excretion rate has been the variable most frequently investigated, although sodium is not a good indicator of the site of action of a drug in the renal tubule, because sodium is reabsorbed or excreted at many sites. Therefore, we investigated the renal handling of PO 4, because PO 4 reabsorption occurs mainly in the proximal tubule, ll,14 Thus, an increased quantity of PO 4 in the urine without a change of the plasma PO 4 level suggests a proximal tubular site of diuretic activity of a drug. We found that nicardipine infusion produced a dramatic increase in PO 4 excretion, even in patients with unchanged or decreased Ccr and plasma PO 4 concentrations (Tables II and Ill) .
In animal studies, 5'6 calcium antagonists increased natriuresis without altering renal blood flow (RBF) or GFR. Abe et al. 15 '16 also reported that redistribution of RBF due to the administration of nicardipine was not such an important factor in sodium diuresis. They suggested that nicardipine had a diuretic effect via an increase of GFR, a decrease in the fractional reabsorption of sodium in the proximal renal tubules, and intrarenal haemodynamic alterations. However, they did not determine which of these three factors provided the main contribution to sodium diuresis due to nicardipine infusion.
Because the systemic administration of a drug alters several variables that influence phosphorus excretion, we have previously evaluated the changes in tubular sodium and PO 4 reabsorption caused in anaesthetized dogs by infusion of nicardipine into the renal artery without any alterations to the systemic and renal circulations. 17 In dogs receiving a low dose of nicardipine (5 ng. kg -l 9 rain -l) into the renal artery, the blood pressure, RBF, and GFR did not change, but urine volume and urinary sodium and PO 4 excretion increased. In the current clinical study, RBF was not determined, but GFR has a stronger influence on PO 4 excretion than RBF. 18 However, Ccr did not change, and there was no relationship between the increase of Ccr and the change of PO 4 excretion during nicardipine infusion. These findings suggest that renal circulatory changes are not an important factor in phosphaturia due to nicardipine infusion.
The relationship between the increase of FENa and FEPO 4 during nicardipine infusion (Figure) suggests that the movement of PO 4 may be associated with that of sodium in the renal tubules. Some investigators have reported that PO 4 reabsorption was highly dependent on the presence of sodium transport, t9'20 Elimination of net sodium transport by inhibiting sodium-potassium ATPase activity with ouabain or by the removal of potassium from the perfusate has been shown to eliminate PO 4 reabsorption. These results suggest that proximal PO 4 reabsorption may be explained by simple chemical coupling with sodium transport. However, phlorizin blocks glucose reabsorption and decreases sodium transport 2~ but increases PO 4 reabsorption. 2~ Thus, the movement of phosphate may be dissociated from the movement of sodium, and the precise cellular mechanisms whereby sodium and PO 4 interact remain unclear.
Excretion volumes ofPO 4 and FEPO 4 and FDRNa were all increased by hANP infusion, and the Ccr was also raised. These findings suggest that this peptide has an influence on the renal circulation and direct effects on the tubular reabsorption of electrolytes. It has been proposed that increments in GFR can fully account for the natriuresis evoked by atrial natriuretic factor(ANF). 22 However, solute and fluid delivery to the last accessible portion of the distal tubule were noted to increase only 2-to 3-fold with ANF, which is far less than the 10-to 50-fold increase in the final urinary solute excretion that commonly occurs. 23 It is therefore reasonable to conclude that ANF-induced natriuresis does not result solely from increments in GFR, or from a decrease in proximal tubular Na reabsorption, but must be due largely to the actions of this peptide at other sites in the kidney. Hammond et al. 24 also reported that hANP infusion produced a brisk phosphaturic response in the absence of any changes in the GFR. Sonnenberg et al. 25 reported that administration of atrial extract failed to increase Na delivery to the endproximal or distal convoluted tubule, whereas Na delivery to the outer medullary collecting duct was increased 3-fold and to the papillary collecting duct nearly 20-fold. Thus, the bulk of the increase in Na excretion that followed ANF administration may be due to reduced collecting duct reabsorption of Na.
Atrial peptide opposes the vascular smooth muscle contraction induced by norepinephrine, angiotensin II, and other vasoconstrictors, 26'27 but the clinical effect of intravenous hANP on the blood pressure is variable because reflex sympathetic stimulation may counter the decrease in blood pressure caused by hANP-induced vasodilation. 9 On the other hand, some studies employing infusion of ANP have suggested that the decrease in blood pressure is due mainly to a decrease in cardiac output and that regional or total peripheral resistance increases. 28, 29 There are large species differences in the vascular actions of ANF, and it elicits both direct and reflexly mediated vasoconstriction. 29 These reports suggest that the effect of hANP on renal function may be influenced by endogenous stress hormones during surgery, although the primary cause of the diuresis due to this peptide may be a direct action on the renal tubule.
In summary, nicardipine and hANP decreased and maintained blood pressure to within the normal range in hypertensive surgical patients, and both drugs induced diuresis. Measurement of PO 4 excretion was useful for assessing drug effects on the renal tubule in a clinical study. Nicardipine may induce phosphaturia due to the inhibition ofPO 4 reabsorption in the proximal renal tubule, but the site of action of hANP on the renal tubule could not be determined in this study.
